| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.02 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |